Page 5 - Mark Neumann News Today

Oklahoma City -- Today (Sunday, June 11), the Brightmusic Summer Festival continues at First Baptist Church in Oklahoma City.

Osterweis Capital Management Inc. grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 37.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 57,750 shares of the biopharmaceutical company’s stock after acquiring an additional 15,855 shares during the quarter. Osterweis Capital Management Inc. […]

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price […]

StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) in a research note issued to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. ITCI has been the topic of several other reports. Canaccord Genuity Group upped their price target on Intra-Cellular Therapies from $93.00 to $98.00 […]

Operator: Good morning and welcome to Intra-Cellular Therapies First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Morgan Stanley initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) in a research note released on Thursday, The Fly reports. The brokerage issued an overweight rating and a $80.00 price target on the biopharmaceutical company’s stock. A number of other research analysts have also recently issued reports on the stock. Canaccord Genuity […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,330,000 shares, an increase of 27.6% from the March 15th total of 2,610,000 shares. Based on an average trading volume of 805,900 shares, the […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating)’s stock price shot up 2.9% on Friday . The stock traded as high as $61.12 and last traded at $61.00. 288,020 shares traded hands during mid-day trading, a decline of 63% from the average session volume of 785,075 shares. The stock had previously closed at $59.28. Wall Street […]

Should You Buy or Sell Intra-Cellular Therapies Stock? Get The Latest ITCI Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its price target boosted by Cantor Fitzgerald from $83.00 to $87.00 in a report published on Wednesday, The Fly reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on the stock. Mizuho lifted their price target on […]